Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes

Overview

Journal Curr Hematol Malig Rep

Publisher Current Science

Specialties Hematology
Oncology

Date 2017 Sep 16

PMID 28913766

Citations 4

Authors

Leylah M Drusbosky

Christopher R Cogle

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: This review discusses the need for computational modeling in myelodysplastic syndromes (MDS) and early test results.

Recent Findings: As our evolving understanding of MDS reveals a molecularly complicated disease, the need for sophisticated computer analytics is required to keep track of the number and complex interplay among the molecular abnormalities. Computational modeling and digital drug simulations using whole exome sequencing data input have produced early results showing high accuracy in predicting treatment response to standard of care drugs. Furthermore, the computational MDS models serve as clinically relevant MDS cell lines for pre-clinical assays of investigational agents. MDS is an ideal disease for computational modeling and digital drug simulations. Current research is focused on establishing the prediction value of computational modeling. Future research will test the clinical advantage of computer-informed therapy in MDS.

Citing Articles

Targeting chromosome 12q amplification in relapsed glioblastoma: the use of computational biological modeling to identify effective therapy-a case report.

Castro M, Khanlou N, Fallah A, Pampana A, Alam A, Lala D Ann Transl Med. 2023; 10(23):1289.

PMID: 36618786 PMC: 9816820. DOI: 10.21037/atm-2022-62.

Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms.

Spinner M, Aleshin A, Santaguida M, Schaffert S, Zehnder J, Scott Patterson A Blood Adv. 2020; 4(12):2768-2778.

PMID: 32569379 PMC: 7322964. DOI: 10.1182/bloodadvances.2020001934.

Myelodysplastic syndromes: moving towards personalized management.

Hellstrom-Lindberg E, Tobiasson M, Greenberg P Haematologica. 2020; 105(7):1765-1779.

PMID: 32439724 PMC: 7327628. DOI: 10.3324/haematol.2020.248955.

Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes.

Drusbosky L, Cogle C Int J Mol Sci. 2020; 21(9).

PMID: 32397113 PMC: 7246771. DOI: 10.3390/ijms21093323.

References

List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E . Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355(14):1456-65. DOI: 10.1056/NEJMoa061292. View

Bejar R, Levine R, Ebert B . Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol. 2011; 29(5):504-15. PMC: 3969457. DOI: 10.1200/JCO.2010.31.1175. View

Traina F, Visconte V, Elson P, Tabarroki A, Jankowska A, Hasrouni E . Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2013; 28(1):78-87. DOI: 10.1038/leu.2013.269. View

Pfeilstocker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Sole F . Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016; 128(7):902-10. PMC: 5161006. DOI: 10.1182/blood-2016-02-700054. View

Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G . Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011; 364(26):2496-506. PMC: 3159042. DOI: 10.1056/NEJMoa1013343. View

Pang W, Schrier S, Weissman I . Age-associated changes in human hematopoietic stem cells. Semin Hematol. 2017; 54(1):39-42. DOI: 10.1053/j.seminhematol.2016.10.004. View

Bejar R, Stevenson K, Caughey B, Lindsley R, Mar B, Stojanov P . Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014; 32(25):2691-8. PMC: 4207878. DOI: 10.1200/JCO.2013.52.3381. View

Lindsley R, Saber W, Mar B, Redd R, Wang T, Haagenson M . Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017; 376(6):536-547. PMC: 5438571. DOI: 10.1056/NEJMoa1611604. View

Malcovati L, Papaemmanuil E, Ambaglio I, Elena C, Galli A, Della Porta M . Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014; 124(9):1513-21. PMC: 4148773. DOI: 10.1182/blood-2014-03-560227. View

10.

Kennedy J, Ebert B . Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome. J Clin Oncol. 2017; 35(9):968-974. PMC: 5455680. DOI: 10.1200/JCO.2016.71.0806. View

11.

Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P . Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22):3616-27. PMC: 3837510. DOI: 10.1182/blood-2013-08-518886. View

12.

Quintas-Cardama A, Daver N, Kim H, DiNardo C, Jabbour E, Kadia T . A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014; 14(5):401-10. PMC: 4167474. DOI: 10.1016/j.clml.2014.03.001. View

13.

Drusbosky L, Medina C, Martuscello R, Hawkins K, Chang M, Lamba J . Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients. Leuk Res. 2016; 52:1-7. DOI: 10.1016/j.leukres.2016.11.004. View

14.

Cogle C . Incidence and Burden of the Myelodysplastic Syndromes. Curr Hematol Malig Rep. 2015; 10(3):272-81. PMC: 4553145. DOI: 10.1007/s11899-015-0269-y. View

15.

Belickova M, Vesela J, Jonasova A, Pejsova B, Votavova H, Dostalova Merkerova M . TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes. Oncotarget. 2016; 7(24):36266-36279. PMC: 5094999. DOI: 10.18632/oncotarget.9200. View

16.

Bejar R, Lord A, Stevenson K, Bar-Natan M, Perez-Ladaga A, Zaneveld J . TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014; 124(17):2705-12. PMC: 4208285. DOI: 10.1182/blood-2014-06-582809. View

17.

Ades L, Itzykson R, Fenaux P . Myelodysplastic syndromes. Lancet. 2014; 383(9936):2239-52. DOI: 10.1016/S0140-6736(13)61901-7. View

18.

Bejar R, Stevenson K, Caughey B, Abdel-Wahab O, Steensma D, Galili N . Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012; 30(27):3376-82. PMC: 3438234. DOI: 10.1200/JCO.2011.40.7379. View

19.

Braun T, Itzykson R, Renneville A, de Renzis B, Dreyfus F, Laribi K . Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 2011; 118(14):3824-31. DOI: 10.1182/blood-2011-05-352039. View

20.

Gerstung M, Papaemmanuil E, Martincorena I, Bullinger L, Gaidzik V, Paschka P . Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet. 2017; 49(3):332-340. PMC: 5764082. DOI: 10.1038/ng.3756. View